Author:
Lee D.H.,Kim S.-W.,Suh C.,Yoon D.H.,Yi E.J.,Lee J.-S.
Funder
Asan Institute for Life Science
Reference20 articles.
1. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes;Li;Clin Cancer Res,2007
2. Epidermal growth factor receptor mutations in lung cancer;Sharma;Nat Rev Cancer,2007
3. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types;Baselga;J Clin Oncol,2002
4. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies;Hidalgo;J Clin Oncol,2001
5. Erlotinib in previously treated non-small cell lung cancer;Shepherd;N Engl J Med,2005
Cited by
69 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献